Online inquiry

IVTScrip™ mRNA-Anti-TNFRSF17, J6M0(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ9553MR)

This product GTTS-WQ9553MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets TNFRSF17 gene. The antibody can be applied in Multiple myeloma (MM) research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_001192.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 608
UniProt ID Q02223
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-TNFRSF17, J6M0(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) (GTTS-WQ9553MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ8624MR IVTScrip™ mRNA-Anti-CD33, HuM195(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA HuM195
GTTS-WQ13800MR IVTScrip™ mRNA-Anti-S, REGN-10933(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA REGN-10933
GTTS-WQ13268MR IVTScrip™ mRNA-Anti-MSTN, PF-06252616(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA PF-06252616
GTTS-WQ6763MR IVTScrip™ mRNA-Anti-TACSTD2, DS-1062(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA DS-1062
GTTS-WQ14934MR IVTScrip™ mRNA-Anti-stx1B, Shigamabs®(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA Shigamabs®
GTTS-WQ7884MR IVTScrip™ mRNA-Anti-MAG, GSK-249320(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA GSK-249320
GTTS-WQ8093MR IVTScrip™ mRNA-Anti-C5, h5G1.1HuG2/G4(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA h5G1.1HuG2/G4
GTTS-WQ15580MR IVTScrip™ mRNA-Anti-AXL, UNII-FFX71LCS5T(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA UNII-FFX71LCS5T
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW